Cynthia M. Butitta
CIK: 0001222082
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (10 total)
- Jun 29, 2026AUTL
Autolus Therapeutics plc
Award(A)DirectShare Option (Right to Buy)
47.5K shares- - Jun 29, 2026AUTL
Autolus Therapeutics plc
Award(A)DirectRestricted Share Units
31.7K shares- - Jun 22, 2026URGN
UroGen Pharma Ltd.
Award(A)DirectRestricted Stock Unit
8K shares- - Jun 22, 2026URGN
UroGen Pharma Ltd.
Award(A)DirectStock Option (right ot buy)
10K shares- - Jun 18, 2026OLMA
Olema Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
29.5K shares- - Nov 26, 2025URGN
UroGen Pharma Ltd.
Exercise(M)Direct2K shares- - Aug 26, 2025URGN
UroGen Pharma Ltd.
Award(A)DirectRestricted Stock Unit
8K shares- - Aug 26, 2025URGN
UroGen Pharma Ltd.
Award(A)DirectStock Option (right ot buy)
10K shares- - Jun 12, 2025IPSC
Century Therapeutics, Inc.
Award(A)DirectStock Option (right to buy)
44K shares- - Jun 11, 2025OLMA
Olema Pharmaceuticals, Inc.
Award(A)DirectStock Option (right to buy)
24.2K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 29, 2026 |  AUTL Autolus Therapeutics plc | Award(A) Share Option (Right to Buy) | 47,500 | - | - | Direct |
| Jun 29, 2026 | AUTL Autolus Therapeutics plc | Award(A) Restricted Share Units | 31,667 | - | - | Direct |
| Jun 22, 2026 |  URGN UroGen Pharma Ltd. | Award(A) Restricted Stock Unit | 8,000 | - | - | Direct |
| Jun 22, 2026 | URGN UroGen Pharma Ltd. | Award(A) Stock Option (right ot buy) | 10,000 | - | - | Direct |
| Jun 18, 2026 |  OLMA Olema Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 29,500 | - | - | Direct |
| Nov 26, 2025 | URGN UroGen Pharma Ltd. | Exercise(M) | 2,000 | - | - | Direct |
| Aug 26, 2025 | URGN UroGen Pharma Ltd. | Award(A) Restricted Stock Unit | 8,000 | - | - | Direct |
| Aug 26, 2025 | URGN UroGen Pharma Ltd. | Award(A) Stock Option (right ot buy) | 10,000 | - | - | Direct |
| Jun 12, 2025 |  IPSC Century Therapeutics, Inc. | Award(A) Stock Option (right to buy) | 44,000 | - | - | Direct |
| Jun 11, 2025 | OLMA Olema Pharmaceuticals, Inc. | Award(A) Stock Option (right to buy) | 24,150 | - | - | Direct |
1-10 of 10 transactions
About BUTITTA CYNTHIA M
BUTITTA CYNTHIA M (SEC CIK 0001222082) files insider reports with the SEC as Director of Autolus Therapeutics plc (AUTL), Director of UroGen Pharma Ltd. (URGN) and Director of Olema Pharmaceuticals, Inc. (OLMA). Signal8 also holds filings tied to 1 other company.
Signal8 holds 8 ownership filings by BUTITTA CYNTHIA M (1 Form 3, 7 Form 4), filed between Jun 13, 2025 and Jul 1, 2026. Those filings report 10 transactions, from Jun 11, 2025 to Jun 29, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on BUTITTA CYNTHIA M's filings is in LONDON.
Recent filings by BUTITTA CYNTHIA M
- Jun 29, 2026: Grants or awards of AUTL derivative securities (2 lines, Form 4, code A).
- Jun 22, 2026: Grants or awards of URGN derivative securities (2 lines, Form 4, code A).
- Jun 18, 2026: Grant or award of OLMA derivative securities (Form 4, code A).
- Nov 26, 2025: Option exercise of URGN shares (Form 4, code M).
- Aug 26, 2025: Grants or awards of URGN derivative securities (2 lines, Form 4, code A).
Other insiders filing for Autolus Therapeutics plc (AUTL)
- Piccina Cintia, U.S. CCO & Country Gen Manager
- YOUNG WILLIAM D, Director
- Rao Madduri Ravin, Director
- Richardson Ryan, Director
- Leiderman Elisabeth, Director
- Iannone Robert, Director